Objective: In spite of new medical and surgical methods a treatment of patients with dilated cardiomyopathy is still a problem in cardiology. In our study we established the EHT as a cardiac support for treatment of dilated cardiomyopathy. Methods: In 14 rats(Sprague Dawley 300 g) we induced dilative cardiomyopathy by 6 weeks doxorubicin treatment (2.5 mg/kg/week). On day 80 we separated the animals into two groups: with EHT implantation (EHT group)(n=6) and control group without therapy (control)(n=8). The EHT was produced as a ring from neonatal rat cardiomycytes in 3D matrigel. We implanted EHT around both ventricles. The attachment of EHT was performed with 4-5 single stitches Prolene 8/0. The follow up was 110 day after beginning of experiment. Results: The overall 110 days survival was 5/6 rats (EHT) and 6/8 (control). One animal (EHT) died directly after operation and two animals on day 90-100 from sever heart failure in control group. Echocardiographic control revealed increased fractional shortening (FS) in the EHT group from 35.4±6.4% to 44.7±6.3% while the control group FS was reduced from 36.3 ±9.5% to 32.8±3.3%. The change in the left ventricular wall thickness wasn't statistical significant. Histological processing of the hearts revealed good integration and adaptation of the EHT. We detected a perfusion of EHT and proved this by blue dextran injection. Conclusion: The EHT therapy seems to improve left ventricle pump function of animals with dilated cardiomyopathy. The integration and perfusion of ENT could be verified. (Supported by TRM, Leipzig)